← Master Registry

Published peptide research references

Octreotide

Governed registry record

25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

  1. Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.

    Anaïs Glatard, Sofia Friberg-Hietala, Lina Keutzer, Anna Hansson, Markus Johnsson, Fredrik Tiberg · Clinical pharmacokinetics · 2025

    DOI: 10.1007/s40262-025-01522-3PMID: 40418492

  2. Octreotide improves human lymphatic fluid transport a translational trial.

    Thomas Holm-Weber, Frederik Skov, Sheyanth Mohanakumar, Lene Thorup, Troels Riis, Mikkel Bring Christensen, David Peick Sonne, Per Bo Jensen, Donna Briggs Bødtkjer, Vibeke Elisabeth Hjortdal · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2024

    DOI: 10.1093/ejcts/ezad380PMID: 37951584

  3. Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.

    Sébastien Gaujoux, Jean-Marc Regimbeau, Guillaume Piessen, Stéphanie Truant, Frantz Foissac, Louise Barbier, Emmanuel Buc, Mustapha Adham, David Fuks, Sophie Deguelte, Fabrice Muscari, Laurent Sulpice · Annals of surgery · 2024

    DOI: 10.1097/sla.0000000000006313PMID: 38662619

  4. Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial.

    Lia C M J Goltstein, Karina V Grooteman, Lucas H P Bernts, Robert C H Scheffer, Robert J F Laheij, Lennard P L Gilissen, Ruud W M Schrauwen, Nynke C Talstra, Abraham T Zuur, Henri Braat, Muhammed Hadithi, Johannes T Brouwer · Gastroenterology · 2024

    DOI: 10.1053/j.gastro.2023.12.020PMID: 38158089

  5. Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial.

    Kamran Bagheri Lankarani, Hoda Safa, Sulmaz Ghahramani, Mohammad Sayari, Seyed-Ali Malekhosseini · Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2022

    DOI: 10.6002/ect.2022.0080PMID: 35867022

  6. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.

    Artak Labadzhyan, L B Nachtigall, M Fleseriu, M B Gordon, M Molitch, L Kennedy, S L Samson, Y Greenman, N Biermasz, M Bolanowski, A Haviv, W Ludlam · Pituitary · 2021

    DOI: 10.1007/s11102-021-01163-2PMID: 34173129

  7. Octreotide for congenital and acquired chylothorax in newborns: A systematic review.

    Carlo Bellini, Rita Cabano, Laura C De Angelis, Tommaso Bellini, Maria G Calevo, Paolo Gandullia, Luca A Ramenghi · Journal of paediatrics and child health · 2018

    DOI: 10.1111/jpc.13889PMID: 29602276

  8. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.

    Anja Rinke, Michael Wittenberg, Carmen Schade-Brittinger, Behnaz Aminossadati, Erdmuthe Ronicke, Thomas M Gress, Hans-Helge Müller, Rudolf Arnold, PROMID Study Group · Neuroendocrinology · 2017

    DOI: 10.1159/000443612PMID: 26731483

  9. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.

    David C Currow, Stephen Quinn, Meera Agar, Belinda Fazekas, Janet Hardy, Nikki McCaffrey, Simon Eckermann, Amy P Abernethy, Katherine Clark · Journal of pain and symptom management · 2015

    DOI: 10.1016/j.jpainsymman.2014.09.013PMID: 25462210

  10. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.

    Jonathan R Strosberg, James C Yao, Emilio Bajetta, Mounir Aout, Bert Bakker, John D Hainsworth, Philippe B Ruszniewski, Eric Van Cutsem, Kjell Öberg, Marianne E Pavel · Endocrine-related cancer · 2015

    DOI: 10.1530/erc-15-0314PMID: 26373569

  11. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.

    Xingang Peng, Peige Wang, Shikuan Li, Guangyong Zhang, Sanyuan Hu · World journal of surgical oncology · 2015

    DOI: 10.1186/s12957-015-0455-3PMID: 25889313

  12. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.

    Marta Cavallin, Patrick S Kamath, Manuela Merli, Silvano Fasolato, Pierluigi Toniutto, Francesco Salerno, Mauro Bernardi, Roberto Giulio Romanelli, Cosimo Colletta, Freddy Salinas, Antonio Di Giacomo, Lorenzo Ridola · Hepatology (Baltimore, Md.) · 2015

    DOI: 10.1002/hep.27709PMID: 25644760

  13. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.

    Carla Chieffo, David Cook, Qinfang Xiang, Lawrence A Frohman · The Journal of clinical endocrinology and metabolism · 2013

    DOI: 10.1210/jc.2013-2262PMID: 23969184

  14. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.

    Sven M Carlsen, Johan Svartberg, Thomas Schreiner, Sylvi Aanderud, Oivind Johannesen, Svein Skeie, Morten Lund-Johansen, Stine L Fougner, Jens Bollerslev, POTA study group · Clinical endocrinology · 2011

    DOI: 10.1111/j.1365-2265.2011.03982.xPMID: 21521254

  15. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

    Marie C Hogan, Tetyana V Masyuk, Linda J Page, Vickie J Kubly, Eric J Bergstralh, Xujian Li, Bohyun Kim, Bernard F King, James Glockner, David R Holmes, Sandro Rossetti, Peter C Harris · Journal of the American Society of Nephrology : JASN · 2010

    DOI: 10.1681/asn.2009121291PMID: 20431041

  16. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.

    Anna Caroli, Luca Antiga, Mariateresa Cafaro, Giorgio Fasolini, Andrea Remuzzi, Giuseppe Remuzzi, Piero Ruggenenti · Clinical journal of the American Society of Nephrology : CJASN · 2010

    DOI: 10.2215/cjn.05380709PMID: 20185596

  17. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

    Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009

    DOI: 10.1200/jco.2009.22.8510PMID: 19704057

  18. Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy.

    Jean Closset, Stephane Journe, Freddy Mboti, Issam El Nakadi, Michel Gelin · Hepato-gastroenterology · 2008

    PMID: 19102400

  19. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.

    Marius N Stan, James A Garrity, Elizabeth A Bradley, John J Woog, Mark M Bahn, Michael D Brennan, Sandra C Bryant, Sara J Achenbach, Rebecca S Bahn · The Journal of clinical endocrinology and metabolism · 2006

    DOI: 10.1210/jc.2006-1105PMID: 16984988

  20. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

    Rudolf Arnold, Anja Rinke, Klaus-Jochen Klose, Hans-Helge Müller, Matthias Wied, Karin Zamzow, Christina Schmidt, Carmen Schade-Brittinger, Peter Barth, Roland Moll, Michael Koller, Michael Unterhalt · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2005

    DOI: 10.1016/s1542-3565(05)00481-7PMID: 16234004

  21. Octreotide in acute bleeding esophageal varices: a prospective randomized study.

    D S Freitas, C Sofia, J M Pontes, C Gregório, J P Cabral, P Andrade, A Rosa, E Camacho, M Ferreira, F Portela, J M Romãozinho, L Tomé · Hepato-gastroenterology · 2000

    PMID: 11100339

  22. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.

    J Rubin, J Ajani, W Schirmer, A P Venook, R Bukowski, R Pommier, L Saltz, P Dandona, L Anthony · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1999

    DOI: 10.1200/jco.1999.17.2.600PMID: 10080605

  23. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis.

    C McKay, J Baxter, C Imrie · International journal of pancreatology : official journal of the International Association of Pancreatology · 1997

    DOI: 10.1007/bf02785915PMID: 9127169

  24. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.

    J P Tauber, M F Poncet, A G Harris, H R Barthel, C Simonetta-Chateauneuf, L Buscail, F Bayard · The Journal of clinical endocrinology and metabolism · 1995

    DOI: 10.1210/jcem.80.11.7593435PMID: 7593435

  25. Octreotide treatment of acromegaly. A randomized, multicenter study.

    S Ezzat, P J Snyder, W F Young, L D Boyajy, C Newman, A Klibanski, M E Molitch, A E Boyd, L Sheeler, D M Cook · Annals of internal medicine · 1992

    DOI: 10.7326/0003-4819-117-9-711PMID: 1416572